Cardiol Therapeutics wins US patent protection for heart-disease drug platform
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Consolidated revenue from operations stood at Rs. 111.05 crore
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
This is the first drug to receive a recommendation for this preventative indication in the European Union
Subscribe To Our Newsletter & Stay Updated